Organization
Universitat Autònoma de Barcelona
10 abstracts
Abstract
Association of androgen receptor gene expression signature and ARV7 with clinical outcome in metastatic hormone-sensitive prostate cancer.Org: Catalan Institute of Oncology-Badalona, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute,
Abstract
Exploring HER2-low disease: Does it impact breast cancer survival?Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology-Hospitalet, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona,
Abstract
The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.Org: INCLIVA Biomedical Research Institute, University of Valencia, Instituto Carlos III, CIBERONC, Biostatistics Unit,
Abstract
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,
Abstract
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).Org: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, H. Universitario Reina Sofía, Universidad de Córdoba, Hospital Universitario Miguel Servet, CIBERONC-ISCIII,
Abstract
Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology, Vall d´Hebron University Hospital, Universitat Autònoma de Barcelona,
Abstract
Effect of high immune-related gene expression on resistance to CDK4/6 inhibitors in advanced breast cancer.Org: Hospital Universitari Germans Trias i Pujol, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol),
Abstract
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barts Cancer Institute, Barts Health NHS Trust and the Royal Free NHS Foundation Trust,
Abstract
Analgesic drugs and risk of ischaemic stroke in patients with ostheoartritis: a real world data case-control studyOrg: Medicines Research Unit, Institut Universitari d’Investigació en Atenció Primària (IDIAPJGol), Barcelona, Institut d’Investigació i Innovació Parc Taulí, Corporació Sanitària Parc Taulí, Sabadell, Universitat Autònoma de Barcelona, Institut Català de la Salut, Barcelona, Unitat de Suport a la Recerca, Institut Universitari d’Investigació en Atenció Primària (IDIAPJGol), Lleida, Spain,
Abstract
BIOMARKERS IN JUVENILE IDIOPATIC ARTHRITIS: DESCRIPTION OF GROUPS WITH DIFFERENT DEGREES OF DISCREPANCY BETWEEN SERUM CALPROTECTIN AND C-REACTIVE PROTEIN.Org: Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona,